Envoy wins additional MJFF grant to advance research
The funds will aid in the development of compounds that act on the motor circuitry that is compromised in Parkinson’s disease (PD) through the modulation of a receptor
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.